Holen Sie sich die Stockscreener-App
64.41
0.62%
0.40
Handel nachbörslich:
64.30
-0.11
-0.17%
Schlusskurs vom Vortag:
$64.01
Offen:
$63.97
24-Stunden-Volumen:
317.97K
Relative Volume:
0.51
Marktkapitalisierung:
$4.10B
Einnahmen:
$112.53M
Nettoeinkommen (Verlust:
$-258.91M
KGV:
-14.88
EPS:
-4.33
Netto-Cashflow:
$-124.42M
1W Leistung:
+0.00%
1M Leistung:
+37.19%
6M Leistung:
+14.51%
1J Leistung:
+47.19%
1-Tages-Spanne:
$63.02
$64.57
1-Wochen-Bereich:
$62.69
$66.09
52-Wochen-Spanne:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
64.41 | 4.10B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals (RYTM) Expected to Announce Earnings on Wednesday - Defense World
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up - simplywall.st
(RYTM) Trading Report - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by LPL Financial LLC - Defense World
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - MSN
Wells Fargo & Company MN Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $74.92 - Defense World
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - The Manila Times
Rare Disease Pioneer Rhythm Pharmaceuticals Unveils Q1 2025 Earnings Date: Key Updates Coming - Stock Titan
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com
Wellington Management Group LLP Sells 2,161 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Raymond James Financial Inc. Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus
Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada
American Century Companies Inc. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN
Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter
Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - marketscreener.com
Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com
Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK
Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada
Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) Surges as Obesity Drug Achieves Ke - GuruFocus
Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News
Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success - insights.citeline.com
Rhythm Pharmaceuticals’ Bold Moves: What’s Next? - timothysykes.com
Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley - TipRanks
Rhythm posts late-stage trial win for lead asset against rare form of obesity - MSN
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish - MSN
BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 By Investing.com - Investing.com Canada
Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha
Rhythm Pharmaceuticals (RYTM) Achieves Success in Phase 3 Obesit - GuruFocus
Rhythm Pharmaceuticals Plans Regulatory Filings After Positive I - GuruFocus
Why Rhythm Pharmaceuticals Stock is Climbing High - TipRanks
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Benzinga
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):